Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720–724 (1993).
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219–2230 (2024).
Wang, X. et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187, 4890–4904.e9 (2024).
Guerra, E., Di Pietro, R., Basile, M., Trerotola, M. & Alberti, S. Cancer-homing CAR-T cells and endogenous immune population dynamics. Int. J. Mol. Sci. 23, 405 (2021).
Si, X. et al. Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell Metab. 36, 176–192.e10 (2024).
Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112–116 (2019).
Peng, L., Sferruzza, G., Yang, L., Zhou, L. & Chen, S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol. Immunol. 21, 1089–1108 (2024).
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
Rosado-Sánchez, I. & Levings, M. K. Building a CAR-Treg: going from the basic to the luxury model. Cell Immunol. 358, 104220 (2020).
Lin, H. et al. Synthetic cells and molecules in cellular immunotherapy. Int. J. Biol. Sci. 20, 2833–2859 (2024).
Chang, Y. et al. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep. 40, 111128 (2022).
Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7–19 (2016).
Zhang, L., Zhao, Y., Dong, Y. & Jiang, X. NK cell-based immunotherapy strategies for myeloid leukemia. Front. Immunol. 16, 1621885 (2025).
Tong, L. et al. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol. Cancer 21, 206 (2022).
Ferrari de Andrade, L. et al. Inhibition of MICA and MICB shedding elicits NK-cell-mediated immunity against tumors resistant to cytotoxic T cells. Cancer Immunol. Res. 8, 769–780 (2020).
Shi, L. et al. Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc. Natl Acad. Sci. USA 115, 11808–11813 (2018).
Meazza, R. et al. Characterization of KIR+ NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C. HLA 100, 119–132 (2022).
Liu, X. et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41, 272–287.e9 (2023).
Park, J.-E. et al. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J. Immunother. Cancer 8, e000873 (2020).
Wang, Y., Shao, W., Mao, J. & Ye, Q. Overcoming resistance and relapse in CAR-T and CAR-NK cell therapies: from bench to bedside. Research 9, 1068 (2026).
Sutlu, T. et al. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum. Gene Ther. 23, 1090–1100 (2012).
Zeng, Y., Gao, M., Lin, D., Du, G. & Cai, Y. Prognostic and immunological roles of MMP-9 in pan-cancer. Biomed. Res. Int. 2022, 2592962 (2022).
Nighot, M. et al. Matrix metalloproteinase MMP-12 promotes macrophage transmigration across intestinal epithelial tight junctions and increases severity of experimental colitis. J. Crohns Colitis 15, 1751–1765 (2021).
Yunna, C., Mengru, H., Lei, W. & Weidong, C. Macrophage M1/M2 polarization. Eur. J. Pharmacol. 877, 173090 (2020).
Rőszer, T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015, 816460 (2015).
Zhao, Y. et al. VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int. J. Biol. Sci. 18, 3845–3858 (2022).
Yu-Ju Wu, C. et al. CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2. Neuro-Oncology 22, 253–266 (2020).
Alvey, C. & Discher, D. E. Engineering macrophages to eat cancer: from ‘marker of self’ CD47 and phagocytosis to differentiation. J. Leukoc. Biol. 102, 31–40 (2017).
Yang, H. et al. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis. Cancer Med. 8, 4245–4253 (2019).
Weiskopf, K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur. J. Cancer 76, 100–109 (2017).
Hagemann, T. et al. “Re-educating” tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 205, 1261–1268 (2008).
Zhang, F. et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 10, 3974 (2019).
Morgan, D. M., Shreffler, W. G. & Love, J. C. Revealing the heterogeneity of CD4+ T cells through single-cell transcriptomics. J. Allergy Clin. Immunol. 150, 748–755 (2022).
Ohkura, N. et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37, 785–799 (2012).
Kawakami, R. et al. Distinct Foxp3 enhancer elements coordinate development, maintenance, and function of regulatory T cells. Immunity 54, 947–961.e8 (2021).
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142–1151 (2005).
Pandiyan, P., Zheng, L., Ishihara, S., Reed, J. & Lenardo, M. J. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8, 1353–1362 (2007).
Abbas, A. K., Trotta, E., Simeonov, R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).
Śledzińska, A. et al. Regulatory T cells restrain interleukin-2- and blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells. Immunity 52, 151–166.e6 (2020).
Wing, J. B., Ise, W., Kurosaki, T. & Sakaguchi, S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41, 1013–1025 (2014).
Tekguc, M., Wing, J. B., Osaki, M., Long, J. & Sakaguchi, S. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl Acad. Sci. USA 118, e2023739118 (2021).
Moreau, J. M., Velegraki, M., Bolyard, C., Rosenblum, M. D. & Li, Z. Transforming growth factor-β1 in regulatory T cell biology. Sci. Immunol. 7, eabi4613 (2022).
Sawant, D. V. et al. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat. Immunol. 20, 724–735 (2019).
Borsellino, G. et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225–1232 (2007).
Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257–1265 (2007).
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. & Tang, Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 18, 749–769 (2019).
Pellicci, D. G., Koay, H.-F. & Berzins, S. P. Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge. Nat. Rev. Immunol. 20, 756–770 (2020).
Cortés-Selva, D., Dasgupta, B., Singh, S. & Grewal, I. S. Innate and innate-like cells: the future of chimeric antigen receptor (CAR) cell therapy. Trends Pharmacol. Sci. 42, 45–59 (2021).
Li, Y.-R., Zhu, Y., Chen, Y. & Yang, L. The clinical landscape of CAR-engineered unconventional T cells. Trends Cancer 11, 520–539 (2025).
Liu, Y. et al. iNKT: a new avenue for CAR-based cancer immunotherapy. Transl. Oncol. 17, 101342 (2022).
Li, Y.-R. et al. Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity. Cancers 14, 2749 (2022).
Tognarelli, E. I. et al. Natural killer T cell diversity and immunotherapy. Cancers 15, 5737 (2023).
Park, Y. H. et al. The iNKT cell ligand α-GalCer prevents murine septic shock by inducing IL10-producing iNKT and B cells. Front. Immunol. 15, 1457690 (2024).
Kim, C. H., Johnston, B. & Butcher, E. C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among Vα24+Vβ11+ NKT cell subsets with distinct cytokine-producing capacity. Blood 100, 11–16 (2002).
Liu, D. et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J. Clin. Invest. 122, 2221–2233 (2012).
Liu, X. et al. NK and NKT cells have distinct properties and functions in cancer. Oncogene 40, 4521–4537 (2021).
Chien, Y., Meyer, C. & Bonneville, M. γδ T cells: first line of defense and beyond. Annu. Rev. Immunol. 32, 121–155 (2014).
Adams, E. J., Gu, S. & Luoma, A. M. Human gamma delta T cells: evolution and ligand recognition. Cell Immunol. 296, 31–40 (2015).
Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178–191 (2023).
Ribot, J. C., Lopes, N. & Silva-Santos, B. γδ T cells in tissue physiology and surveillance. Nat. Rev. Immunol. 21, 221–232 (2021).
Riond, J. et al. In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by γδ T and NK cells during the early steps of tumor growth. Cancer Immun. 9, 10 (2009).
Wang, H. et al. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. J. Immunother. Cancer 9, e003339 (2021).
Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. & Tanabe, K. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol. Immunother. 60, 1075–1084 (2011).
Xu, Y. et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol. Immunol. 18, 427–439 (2021).
Siegers, G. M. & Lamb, L. S. Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field? Mol. Ther. 22, 1416–1422 (2014).
Almeida, A. R. et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin. Cancer Res. 22, 5795–5804 (2016).
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
Marinović, S. et al. NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis. Sci. Immunol. 8, eadd1599 (2023).
Angelini, D. F. et al. FcγRIII discriminates between 2 subsets of Vγ9Vδ2 effector cells with different responses and activation pathways. Blood 104, 1801–1807 (2004).
Gherardin, N. A. et al. Human blood MAIT cell subsets defined using MR1 tetramers. Immunol. Cell Biol. 96, 507–525 (2018).
Treiner, E. et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422, 164–169 (2003).
Legoux, F., Salou, M. & Lantz, O. MAIT cell development and functions: the microbial connection. Immunity 53, 710–723 (2020).
Sobkowiak, M. J. et al. Tissue-resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL-17. Eur. J. Immunol. 49, 133–143 (2019).
Salio, M. et al. Activation of human mucosal-associated invariant T cells induces CD40L-dependent maturation of monocyte-derived and primary dendritic cells. J. Immunol. 199, 2631–2638 (2017).
Li, Y.-R. et al. Mucosal-associated invariant T cells for cancer immunotherapy. Mol. Ther. 31, 631–646 (2023).
Kurioka, A. et al. Shared and distinct phenotypes and functions of human CD161++ Vα7.2+ T cell subsets. Front. Immunol. 8, 1031 (2017).
Rea, A. et al. Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression. Nat. Immunol. 26, 582–594 (2025).
Yi, F. et al. CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit. Nat. Cancer 6, 1638–1655 (2025).
Vivier, E. et al. Natural killer cell therapies. Nature 626, 727–736 (2024).
Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520–531 (2018).
Klingemann, H., Boissel, L. & Toneguzzo, F. Natural killer cells for immunotherapy – advantages of the NK-92 cell line over blood NK cells. Front. Immunol. 7, 91 (2016).
Handgretinger, R., Lang, P. & André, M. C. Exploitation of natural killer cells for the treatment of acute leukemia. Blood 127, 3341–3349 (2016).
Williams, B. A. et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget 8, 89256–89268 (2017).
Boyiadzis, M. et al. Phase 1 clinical trial of adoptive immunotherapy using ‘off-the-shelf’ activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy 19, 1225–1232 (2017).
Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat. Med. 30, 772–784 (2024).
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
Huang, R. et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial. Exp. Hematol. Oncol. 14, 1 (2025).
Lin, Y. et al. Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies. J. Hematol. Oncol. 18, 57 (2025).
Heipertz, E. L. et al. Current perspectives on ‘off-the-shelf’ allogeneic NK and CAR-NK cell therapies. Front. Immunol. 12, 732135 (2021).
Lin, X. et al. IPSC-derived CAR-NK cells for cancer immunotherapy. Biomed. Pharmacother. 165, 115123 (2023).
Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624–636 (2021).
Lam, P. Y. et al. Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. Clin. Transl. Med. 15, e70140 (2025).
Acharya, S. et al. CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3ζ/ZAP70 signaling axis. Cancer Discov. 14, 1879–1900 (2024).
Zhang, P. et al. CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy. Exp. Hematol. Oncol. 14, 28 (2025).
Kok, N. et al. CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. iScience 28, 112548 (2025).
Chang, Y.-H. et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 73, 1777–1786 (2013).
Guillerey, C., Huntington, N. D. & Smyth, M. J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016).
Li, Y., Hermanson, D. L., Moriarity, B. S. & Kaufman, D. S. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181–192.e5 (2018).
Li, X. et al. A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy. J. Hematol. Oncol. 17, 116 (2024).
Reiss, K. A. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171–1182 (2025).
Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102–116 (2024).
Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J. Hematol. Oncol. 13, 153 (2020).
Choi, J. U. et al. Lentivirus-based production of human chimeric antigen receptor macrophages from peripheral blood. Biomark Res. 13, 1 (2025).
Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, 2103258 (2021).
Yang, Z. et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J. Control. Release 360, 718–733 (2023).
Lin, Z. P. et al. Macrophages actively transport nanoparticles in tumors after extravasation. ACS Nano 16, 6080–6092 (2022).
Jaynes, J. M. et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci. Transl. Med. 12, eaax6337 (2020).
Gao, L. et al. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. J. Nanobiotechnol. 21, 56 (2023).
Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).
Zhang, W. et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br. J. Cancer 121, 837–845 (2019).
Du, F. et al. An engineered α1β1 integrin-mediated FcγRI signaling component to control enhanced CAR macrophage activation and phagocytosis. J. Control. Release 377, 689–703 (2025).
Niu, Z. et al. Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity. J. Pathol. 253, 247–257 (2021).
Morrissey, M. A. et al. Chimeric antigen receptors that trigger phagocytosis. eLife 7, e36688 (2018).
Dai, H. et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J. Hepatol. 80, 913–927 (2024).
Chen, Y. et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J. Transl. Med. 21, 654 (2023).
Zhang, J. et al. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Rep. 18, 585–596 (2023).
Shah, Z. et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell 31, 803–817.e6 (2024).
Landwehr-Kenzel, S. et al. Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy. Kidney Int. 93, 1452–1464 (2018).
Noyan, F. et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am. J. Transplant. 17, 917–930 (2017).
Tenspolde, M. et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J. Autoimmunity 103, 102289 (2019).
Hippen, K. L. et al. Massive ex vivo expansion of human natural regulatory T cells (Tregs)) with minimal loss of in vivo functional activity. Sci. Transl. Med. 3, 83ra41 (2011).
Vallotton, L. et al. Monitoring of CD4+CD25highIL-7Rαhigh activated T cells in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 6, 2025–2033 (2011).
Procaccini, C. & Matarese, G. Regulatory T cells, mTOR kinase, and metabolic activity. Cell Mol. Life Sci. 69, 3975–3987 (2012).
Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).
Selvaraj, R. K. & Geiger, T. L. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-β. J. Immunol. 179, 11 (2007).
Dardalhon, V. et al. IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3– effector T cells. Nat. Immunol. 9, 1347–1355 (2008).
Fransson, M. et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J. Neuroinflammation 9, 112 (2012).
Morikawa, H. et al. Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation. Proc. Natl Acad. Sci. USA 111, 5289–5294 (2014).
Akamatsu, M. et al. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19. Sci. Immunol. 4, eaaw2707 (2019).
Mikami, N. et al. Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation. Proc. Natl Acad. Sci. USA 117, 12258–12268 (2020).
Mikami, N., Kawakami, R., Sugimoto, A., Arai, M. & Sakaguchi, S. Generating functionally stable and antigen-specific Treg cells from effector T cells for cell therapy of inflammatory diseases. Sci. Transl. Med. 17, eadr6049 (2025).
Dawson, N. A. J. et al. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Sci. Transl. Med. 12, eaaz3866 (2020).
Boroughs, A. C. et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight 5, e126194 (2019).
Shrestha, B. et al. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. J. Clin. Invest. 130, 4652–4662 (2020).
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 costimulation: from mechanism to therapy. Immunity 44, 973–988 (2016).
Lamarthée, B. et al. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction. Nat. Commun. 12, 6446 (2021).
Heczey, A. et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat. Med. 26, 1686–1690 (2020).
Zhang, Y. et al. α-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials. Front. Immunol. 10, 1126 (2019).
Tian, G. et al. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J. Clin. Invest. 126, 2341–2355 (2016).
Ngai, H. et al. IL-21 selectively protects CD62L+ NKT cells and enhances their effector functions for adoptive immunotherapy. J. Immunol. 201, 2141–2153 (2018).
Li, Y.-R. et al. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep. Med. 2, 100449 (2021).
Li, Y.-R. et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol. Ther. 32, 1849–1874 (2024).
Thongsin, N., Suwanpitak, S. & Wattanapanitch, M. CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2). Stem Cell Res. 71, 103138 (2023).
Li, Y.-R. et al. Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nat. Protoc. 20, 1352–1388 (2025).
Li, Y.-R. et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat. Biotechnol. 43, 329–344 (2025).
Alexander, A. A. Z. et al. Isopentenyl pyrophosphate-activated CD56+ γδ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 14, 4232–4240 (2008).
Ashihara, E. et al. Isopentenyl pyrophosphate secreted from zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells. Biochem. Biophys. Res. Commun. 463, 650–655 (2015).
Rozenbaum, M. et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front. Immunol. 11, 1347 (2020).
Deniger, D. C. et al. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol. Ther. 21, 638–647 (2013).
Zhai, X. et al. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity. Am. J. Cancer Res. 11, 79–91 (2021).
Nishimoto, K. P. et al. Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin. Transl. Immunol. 11, e1373 (2022).
Jiang, L. et al. B7-H3-targeted CAR-Vδ1T cells exhibit potent broad-spectrum activity against solid tumors. Cancer Res. 84, 4066–4080 (2024).
Capsomidis, A. et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol. Ther. 26, 354–365 (2018).
Landoni, E. et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat. Commun. 15, 89 (2024).
Huang, S. et al. BiTE-secreting CAR-γδT as a dual targeting strategy for the treatment of solid tumors. Adv. Sci. 10, 2206856 (2023).
Imai, C., Iwamoto, S. & Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376–383 (2005).
Boissel, L., Betancur, M., Wels, W. S., Tuncer, H. & Klingemann, H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk. Res. 33, 1255–1259 (2009).
Altvater, B. et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin. Cancer Res. 15, 4857–4866 (2009).
Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405, 127–136 (2025).
Liu, R. et al. A soluble NK-CAR mediates the specific cytotoxicity of NK cells toward the target CD20+ lymphoma cells. Aging Dis. 13, 1576–1588 (2022).
Yang, N. et al. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J. Transl. Med. 22, 274 (2024).
Oelsner, S. et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Int. J. Cancer 145, 1935–1945 (2019).
Chen, K. H. et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia 31, 2151–2160 (2017).
Voynova, E. et al. Increased activity of a NK-specific CAR-NK framework targeting CD3 and CD5 for T-cell leukemias. Cancers 14, 524 (2022).
Xu, Y. et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J. Hematol. Oncol. 12, 49 (2019).
Jiang, J. et al. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia 37, 1660–1670 (2023).
Liao, C. et al. CD38-specific CAR integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells. Adv. Sci. 10, 2207394 (2023).
Tang, X. et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am. J. Cancer Res. 8, 1083–1089 (2018).
Herrera, L. et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci. Rep. 9, 18729 (2019).
Wang, X. et al. Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 4, 1950–1964 (2020).
Chitadze, G., Bhat, J., Lettau, M., Janssen, O. & Kabelitz, D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand. J. Immunol. 78, 120–129 (2013).
Xiao, L. et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol. Ther. 27, 1114–1125 (2019).
Schönfeld, K. et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 23, 330–338 (2015).
Nowakowska, P. et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol. Immunother. 67, 25–38 (2018).
Zhang, C. et al. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J. Natl Cancer Inst. 108, djv375 (2016).
Burger, M. C. et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro-Oncology 25, 2058–2071 (2023).
Han, J. et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 5, 11483 (2015).
Lin, Y.-Z. et al. Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells. Am. J. Cancer Res. 11, 4455–4469 (2021).
Cao, B. et al. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Biochem. Biophys. Res. Commun. 524, 96–102 (2020).
Cao, B. et al. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int. J. Biol. Sci. 17, 3850–3861 (2021).
Hu, Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci. Rep. 10, 2815 (2020).
Genßler, S. et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology 5, e1119354 (2016).
Peng, L. et al. In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat. Biotechnol. 43, 752–761 (2025).
Wang, X. et al. An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell 188, 4225–4238.e12 (2025).
Fu, Y. et al. Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 84, 1811–1821 (2025).
Olona, A. et al. Sphingolipid metabolism during Toll-like receptor 4 (TLR4)-mediated macrophage activation. Br. J. Pharmacol. 178, 4575–4587 (2021).
Shen, J. et al. Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. Cell Stem Cell 31, 1003–1019.e9 (2024).
Zhang, H. et al. Silencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumors. Cell Mol. Immunol. 21, 1335–1349 (2024).
Lampropoulou, V. et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab. 24, 158–166 (2016).
Wang, X. et al. Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat. Commun. 14, 5778 (2023).
Bluestone, J. A. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7, 315ra189 (2015).
Brunstein, C. G. et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117, 1061–1070 (2011).
Landwehr-Kenzel, S. et al. Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Mol. Ther. 30, 2298–2314 (2022).
Frikeche, J. et al. MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis. J. Neuroinflammation 21, 268 (2024).
Blat, D., Zigmond, E., Alteber, Z., Waks, T. & Eshhar, Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol. Ther. 22, 1018–1028 (2014).
Obarorakpor, N. et al. Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes. Front. Immunol. 14, 1207108 (2023).
Good, Z. et al. Post-infusion CAR Treg cells identify patients resistant to CD19-CAR therapy. Nat. Med. 28, 1860–1871 (2022).
Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D. & Fricke, S. CAR T cells for treating autoimmune diseases. RMD Open 9, e002907 (2023).
Müller, F. et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).
Imura, Y., Ando, M., Kondo, T., Ito, M. & Yoshimura, A. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD. JCI Insight 5, e136185 (2020).
Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nat. Commun. 15, 2542 (2024).
Jacquemin, C. et al. OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response. Immunity 42, 1159–1170 (2015).
Rui, X. et al. Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity. Sci. Transl. Med. 16, eadj9331 (2024).
Cui, Y. et al. IL23R-specific CAR Tregs for the treatment of Crohn’s disease. J. Crohns Colitis 19, jjae135 (2024).
Martin, A., Daris, M., Johnston, J. A. & Cui, J. HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease. Cytotherapy 23, 131–136 (2021).
MacDonald, K. G. et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J. Clin. Invest. 126, 1413–1424 (2016).
Ellis, G. I. et al. Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque. Cell Rep. Med. 3, 100614 (2022).
Bézie, S. et al. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice. Blood Adv. 3, 3522–3538 (2019).
Sakaguchi, S. et al. Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541–566 (2020).
Bolivar-Wagers, S., Larson, J. H., Jin, S. & Blazar, B. R. Cytolytic CD4+ and CD8+ regulatory T-cells and implications for developing immunotherapies to combat graft-versus-host disease. Front. Immunol. 13, 864748 (2022).
Barra, J. M. et al. Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells. Cell Rep. 43, 114994 (2024).
Heczey, A. et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124, 2824–2833 (2014).
Xu, X. et al. NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin. Cancer Res. 25, 7126–7138 (2019).
Li, Y.-R. et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med 6, 100804 (2025).
Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat. Med. 29, 1379–1388 (2023).
Rischer, M. et al. Human γδ T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br. J. Haematol. 126, 583–592 (2004).
Frieling, J. S. et al. γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci. Adv. 9, eadf0108 (2023).
Ang, W. X. et al. Electroporation of NKG2D RNA CAR improves Vγ9Vδ2 T cell responses against human solid tumor xenografts. Mol. Ther. Oncolytics 17, 421–430 (2020).
Dogan, M. et al. Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy. J. Immunol. 209, 1523–1531 (2022).
Li, Y.-R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725–744 (2025).
Milone, M. C. & O’Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529–1541 (2018).
Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).
Albinger, N. et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 12, 61 (2022).
Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519–531 (2011).
Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532–1535 (2004).
Liang, Y., Xu, Q. & Gao, Q. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. Front. Immunol. 14, 1291619 (2023).
Leslie, J. et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 71, 2093–2106 (2022).
Sun, S. et al. Smart liposomal nanocarrier enhanced the treatment of ischemic stroke through neutrophil extracellular traps and cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway inhibition of ischemic penumbra. ACS Nano 17, 17845–17857 (2023).
Harris, J. D. et al. Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells. J. Immunol. Regen. Med. 20, 100074 (2023).
Chang, Y. et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat. Commun. 14, 2266 (2023).